IRISH MEDICINES BOARD
The Irish Medicines Board, officially known as the Health Products Regulatory Authority (HPRA), is a pivotal entity in the pharmaceutical and healthcare industry, headquartered in Ireland (IE). Established in 1996, the HPRA plays a crucial role in ensuring the safety and efficacy of medicines and medical devices across the country and the European Union. With a focus on regulatory compliance, the HPRA oversees the approval and monitoring of medicinal products, ensuring they meet stringent safety standards. Its core services include the evaluation of new medicines, pharmacovigilance, and the regulation of clinical trials, making it a trusted authority in the sector. Recognised for its commitment to public health, the HPRA has achieved significant milestones, including the implementation of advanced regulatory frameworks that enhance patient safety. Its market position is bolstered by a reputation for excellence in regulatory practices, contributing to the overall integrity of the healthcare system in Ireland.
DitchCarbon Score
How does IRISH MEDICINES BOARD's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
IRISH MEDICINES BOARD's score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
IRISH MEDICINES BOARD's reported carbon emissions
The Irish Medicines Board (IMB) currently does not have available carbon emissions data, as indicated by the absence of specific figures for kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the organisation. As such, the IMB has not publicly committed to any specific climate initiatives or reduction strategies at this time. In the context of the pharmaceutical industry, organisations are increasingly focusing on sustainability and carbon footprint reduction, but the IMB has yet to disclose any related commitments or performance metrics. Without emissions data or reduction initiatives, it is unclear how the IMB aligns with industry standards for climate action.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
IRISH MEDICINES BOARD is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
